{
  "denotations": [
    {
      "id": "T1",
      "obj": "Chemical",
      "span": {
        "begin": 52,
        "end": 61
      }
    },
    {
      "id": "T2",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 73,
        "end": 77
      }
    },
    {
      "id": "T3",
      "obj": "Disease",
      "span": {
        "begin": 86,
        "end": 91
      }
    },
    {
      "id": "T4",
      "obj": "Chemical",
      "span": {
        "begin": 152,
        "end": 160
      }
    },
    {
      "id": "T5",
      "obj": "Disease",
      "span": {
        "begin": 194,
        "end": 199
      }
    },
    {
      "id": "T6",
      "obj": "Chemical",
      "span": {
        "begin": 260,
        "end": 269
      }
    },
    {
      "id": "T10",
      "obj": "Chemical",
      "span": {
        "begin": 194,
        "end": 212
      }
    }
  ],
  "sourcedb": "PubMed",
  "sourceid": "18980981_6",
  "text": "EXPERIMENTAL DESIGN : In a cell culture model of an erlotinib -sensitive EGFR -mutant NSCLC cell line , we tested the hypothesis that prior exposure to platinum agents , a standard component of NSCLC chemotherapy treatment , affects the subsequent response to erlotinib ."
}
